Puma Biotechnology Inc (NYSE:PBYI) Shares Bought by Rothschild Asset Management Inc.

Rothschild Asset Management Inc. increased its position in Puma Biotechnology Inc (NYSE:PBYI) by 40.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 33,404 shares of the biopharmaceutical company’s stock after buying an additional 9,658 shares during the period. Rothschild Asset Management Inc. owned approximately 0.09% of Puma Biotechnology worth $2,920,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of Montreal Can raised its position in shares of Puma Biotechnology by 1.8% in the second quarter. Bank of Montreal Can now owns 5,351 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 97 shares during the period. Legal & General Group Plc raised its position in shares of Puma Biotechnology by 2.8% in the first quarter. Legal & General Group Plc now owns 9,297 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 249 shares during the period. Creative Planning raised its position in shares of Puma Biotechnology by 62.3% in the second quarter. Creative Planning now owns 2,862 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 1,099 shares during the period. Swiss National Bank raised its position in shares of Puma Biotechnology by 2.1% in the first quarter. Swiss National Bank now owns 54,730 shares of the biopharmaceutical company’s stock worth $2,036,000 after buying an additional 1,100 shares during the period. Finally, Strs Ohio acquired a new position in shares of Puma Biotechnology during the second quarter worth about $122,000. 80.98% of the stock is owned by hedge funds and other institutional investors.

Puma Biotechnology Inc (NYSE PBYI) traded down 1.18% during mid-day trading on Friday, reaching $79.75. 744,991 shares of the company traded hands. The company’s 50-day moving average is $87.66 and its 200-day moving average is $58.07. The stock’s market capitalization is $2.97 billion. Puma Biotechnology Inc has a 12-month low of $28.35 and a 12-month high of $98.85.

Puma Biotechnology (NYSE:PBYI) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by $0.78. Equities analysts predict that Puma Biotechnology Inc will post ($8.62) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.com-unik.info/2017/08/19/puma-biotechnology-inc-nysepbyi-stake-boosted-by-rothschild-asset-management-inc-updated.html.

A number of brokerages recently issued reports on PBYI. BidaskClub upgraded shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a report on Monday, July 31st. J P Morgan Chase & Co reissued a “buy” rating on shares of Puma Biotechnology in a research report on Tuesday, August 1st. Bank of America Corporation reissued a “buy” rating and set a $117.00 target price (up previously from $100.00) on shares of Puma Biotechnology in a research report on Friday, July 21st. Cowen and Company reissued an “outperform” rating and set a $120.00 target price (up previously from $91.00) on shares of Puma Biotechnology in a research report on Saturday, July 22nd. Finally, Leerink Swann reissued an “outperform” rating and set a $125.00 target price (up previously from $115.00) on shares of Puma Biotechnology in a research report on Wednesday, July 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. Puma Biotechnology presently has an average rating of “Buy” and a consensus target price of $109.56.

In related news, insider Alan H. Auerbach sold 13,175 shares of the stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $94.73, for a total transaction of $1,248,067.75. Following the sale, the insider now directly owns 4,170,623 shares of the company’s stock, valued at $395,083,116.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Richard Paul Bryce sold 1,998 shares of the stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $94.48, for a total value of $188,771.04. Following the sale, the senior vice president now directly owns 27,246 shares in the company, valued at $2,574,202.08. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,010,261 shares of company stock worth $159,425,452. Insiders own 22.70% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)

What are top analysts saying about Puma Biotechnology Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Puma Biotechnology Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit